AU Patent

AU2019346521B2 — Methods of treating myeloproliferative disorders

Assigned to Impact Biomedicines Inc · Expires 2025-05-08 · 1y expired

What this patent protects

The present disclosure provides methods of mitigating thiamine deficiency.

USPTO Abstract

The present disclosure provides methods of mitigating thiamine deficiency.

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

Patent Metadata

Patent number: AU2019346521B2
Jurisdiction: AU
Classification: —
Expires: 2025-05-08
Drug substance claim: No
Drug product claim: No
Assignee: Impact Biomedicines Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.